Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of intranasal (R)-ketamine hydrochloride in adults with treatment-resistant depression
CTR20250133Phase 2Active
- Sponsor
- Jiangsu Nhwa Pharmaceutical
- Start
- Mar 2025
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of r-ketamine in treatment-resistant depression (TRD), major depressive disorder (MDD), sponsored by Jiangsu Nhwa Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
r-ketamine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20250133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250133.